RT Journal Article
SR Electronic
T1 Hemochromatosis Neural Archetype Reveals Iron Disruption in Motor Circuits
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.22.22281386
DO 10.1101/2022.10.22.22281386
A1 Loughnan, Robert
A1 Ahern, Jonathan
A1 Boyle, Mary
A1 Jernigan, Terry L.
A1 Hagler, Donald J.
A1 Iversen, John R.
A1 Frei, Oleksandr
A1 Smith, Diana M.
A1 Andreassen, Ole
A1 Zaitlen, Noah
A1 Sugrue, Leo
A1 Thompson, Wesley K.
A1 Dale, Anders
A1 Schork, Andrew J.
A1 Fan, Chun Chieh
YR 2024
UL http://medrxiv.org/content/early/2024/03/04/2022.10.22.22281386.abstract
AB Our understanding of brain iron regulation and its disruption in disease is currently lacking. We previously found that motor circuitry is susceptible to the cumulative neurotoxic effects of excessive iron, leading to the manifestation of Parkinson’s disease. However, beyond a few well-known genes involved in peripheral iron metabolism, the underlying molecular mechanisms regulating central iron levels remain unclear. To bridge this gap, we generated scores in neurotypical individuals based on the archetypal brain iron accumulation observed in magnetic resonance imaging scans of individuals who exhibit excessive absorption of dietary iron and hemochromatosis risk. Genome-wide analysis, using common-variant SNP-array and rare-variant exome data, demonstrated this archetypal brain iron accumulation pattern is highly heritable, revealing both known and novel loci associated with iron homeostasis, and causally driven by peripheral iron levels. Our score predicted abnormalities in gait and revealed a U-shape relationship with PD risk - identifying a group of individuals with a 3-fold increased risk for this disorder. Taken together these results establish a hormetic relationship between brain iron and PD risk, in which central iron levels are strongly determined by genetics via peripheral iron. We believe this framework combining forward and reverse genetics represents a powerful new study design to understand genomic drivers underlying high dimensional phenotypes.Competing Interest StatementDr. Andreassen has received speaker's honorarium from Lundbeck, and is a consultant to HealthLytix. Dr. Dale is a Founder of and holds equity in CorTechs Labs, Inc, and serves on its Scientific Advisory Board. He is a member of the Scientific Advisory Board of Human Longevity, Inc. and receives funding through research agreements with General Electric Healthcare and Medtronic, Inc. The terms of these arrangements have been reviewed and approved by UCSD in accordance with its conflict of interest policies. The other authors declare no competing interests.Funding StatementThis work was supported by grants R01MH122688 and RF1MH120025 funded by the National Institute for Mental Health (NIMH) in addition to Lundbeck Foundation fellowship (R335-2019-2318). ABCD federal partners under grant numbers: U01DA041022, U01DA041028, U01DA041048, U01DA041089, U01DA041106, U01DA041117, U01DA041120, U01DA041134, U01DA041148, U01DA041156, U01DA041174, U24DA041123, and U24DA041147Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available human data that were originally located at: https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access and https://abcdstudy.orgI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUK Biobank data was accessed under accession number 27412. Summary statistics from GWAS of Hemochromatosis Brain PVS are available for download. Researchers can apply for access to UK Biobank data at https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access. The ABCD data used in this came from [NIMH Data Archive Digital Object Identifier (10.15154/1523041)]. This data is available to approved researchers, find more information at https://abcdstudy.org.